References
- Jung KW, Won YJ, Kong HJ, Lee ES; Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2015. Cancer Res Treat 2018;50:303-316
- Shin A, Kim J, Park S. Gastric cancer epidemiology in Korea. J Gastric Cancer 2011;11:135-140
- Schlansky B, Sonnenberg A. Epidemiology of noncardia gastric adenocarcinoma in the United States. Am J Gastroenterol 2011;106:1978-1985
- Hwang JE, Kim SH, Jin J, Hong JY, Kim MJ, Jung SH, et al. Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer. Clin Exp Metastasis 2014;31:25-32
- Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016;14:1286-1312
- Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer 2019;19:1-48
- Shirabe K, Wakiyama S, Gion T, Watanabe M, Miyazaki M, Yoshinaga K, et al. Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature. HPB (Oxford) 2006;8:89-92
- Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909
- Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434
- Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-731
- Sohaib SA, Turner B, Hanson JA, Farquharson M, Oliver RT, Reznek RH. CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol 2000;73:1178-1184
- Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology 2002;225:416-419
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247
- Ito H, Takemura N, Ono Y, Sato T, Mise Y, Inoue Y, et al. Gastric cancer liver metastasis: optimal management for oligo-metastatic disease. J Clin Oncol 2019;37:136-136
- Ryu T, Takami Y, Wada Y, Tateishi M, Matsushima H, Yoshitomi M, et al. Oncological outcomes after hepatic resection and/or surgical microwave ablation for liver metastasis from gastric cancer. Asian J Surg 2019;42:100-105
- Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst 2000;92:179-181
- Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 2006;24:3245-3251
- Reiner CS, Karlo C, Petrowsky H, Marincek B, Weishaupt D, Frauenfelder T. Preoperative liver volumetry: how does the slice thickness influence the multidetector computed tomography- and magnetic resonance-liver volume measurements? J Comput Assist Tomogr 2009;33:390-397
- Desar IM, Van Herpen CM, Van Laarhoven HW, Barentsz JO, Oyen WJ, Van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009;35:309-321
- Trillet-Lenoir V, Freyer G, Kaemmerlen P, Fond A, Pellet O, Lombard-Bohas C, et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol 2002;75:903-908
- Banerjee S, Wang DS, Kim HJ, Sirlin CB, Chan MG, Korn RL, et al. A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology 2015;62:792-800
- Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sportoletti C, et al. Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology 2016;279:432-442
- Hallinan JT, Venkatesh SK, Peter L, Makmur A, Yong WP, So JB. CT volumetry for gastric carcinoma: association with TNM stage. Eur Radiol 2014;24:3105-3114
- Lee SM, Kim SH, Lee JM, Im SA, Bang YJ, Kim WH, et al. Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer. Abdom Imaging 2009;34:430-440
- Kikuchi S, Hiki Y, Shimao H, Sakakibara Y, Kakita A. Tumor volume: a novel prognostic factor in patients who undergo curative resection for gastric cancer. Langenbecks Arch Surg 2000;385:225-228
- Egger ME, Cannon RM, Metzger TL, Nowacki M, Kelly L, Tatum C, et al. Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. J Am Coll Surg 2013;216:845-856; discussion 856-857
- Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008;26:183-189
- Kikuchi S, Sakuramoto S, Kobayashi N, Shimao H, Sakakibara Y, Sato K, et al. A new staging system based on tumor volume in gastric cancer. Anticancer Res 2001;21:2933-2936
- Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH. Liver metastases in the era of molecular targeted therapy: new faces of treatment response. AJR Am J Roentgenol 2013;201:W15-28
- Krajewski KM, Braschi-Amirfarzan M, DiPiro PJ, Jagannathan JP, Shinagare AB. Molecular targeted therapy in modern oncology: imaging assessment of treatment response and toxicities. Korean J Radiol 2017;18:28-41
- Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302:2338-2344
- Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics 2013;33:1323-1341
- Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143-e152
- Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134
- Lee IS, Choi SJ, Seo CR, Kim JS. Comparison of the response evaluation criteria in solid tumors with volumetric measurement for evaluation of response and overall survival with liver metastases from colorectal cancer. J Korean Soc Radiol 2019;80:906-918
- Adam R, Wicherts DA, De Haas RJ, Ciacio O, Levi F, Paule B, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009;27:1829-1835
- Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243-9249
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines). Gastric cancer, version 2. 2018. Available at. https://www.nccn.org. Assessed Apr 28, 2020